Conflicts of interest include but are not limited to royal ty or consulting fees, speaking honoraria, advisory board appointments, publicly -traded or privately -held equities, stock options, intellectual property, and gifts. The Duke University School of Medicine’s RIO reviews and manages research -related conflicts of interest . The Principal Investigator and Sub- Investigators must report conflicts of interest annually and within 10 days of a change in status, and when applicable, must have a documented management plan that is developed in conjunction with the Duke R IO and approved by the IRB/IEC. 16.9 Costs to the Subject The c osts of the study drug , Td, blood for immune monitoring, and the leukapheresis associated with this study are provided free of charge. The patient or third party payer (HMO or insurance company) will be responsible for all other medical costs including the standard of care chemotherapy , radiation therapy (if applicable) , blood work, and MRI scans . Some insurance companies and HMOs may not reimburse patients for costs arising from investigational studies . No compensation for participation in this study will be given. 16.10 Registration Procedure After patients have been enrolled, protocol -specific information and subject registration will be entered into the Velos e- Research software system . This system is managed by the School of Medicine. Patients will also be entered under this protocol study in the Duke Epic Maestro Care system . Pro00054746: RESIST Study Version: 20171011 PT-PhI-II v05.22.12 Duke Cancer Institute Page 48 CONFIDENTIAL 17 REFERENCES 1. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA. Gene the rapy with human and mouse T -cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood.